BOSTON , June 9, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that it has entered into a definitive merger agreement (the "Merger Agreement") with Concentra Biosciences, LLC ("Concentra"), whereby Concentra... Read More

Presented preclinical data for potentially differentiated HER3 ADC, EO-1022, at AACR Annual Meeting Expects to file IND application for EO-1022 in 2026 Cash runway into 2H 2026 BOSTON , May 15, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant... Read More

EO-1022 is a potentially differentiated HER3 ADC designed to address significant unmet needs across multiple solid tumors On-track to file IND application in 2026 BOSTON , April 25, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical... Read More

Abstract accepted for late-breaking poster presentation EO-1022 is a potentially differentiated HER3 ADC being developed for the treatment of solid tumors, including breast and non-small cell lung cancers On-track to file an Investigational New Drug (IND) application in 2026 BOSTON , March 25, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development... Read More

Continuing to advance potentially differentiated HER3 ADC, EO-1022, which utilizes an MMAE payload and glycan site-specific conjugation Plan to present preclinical data for EO-1022 at AACR Annual Meeting 2025 and to file an Investigational New Drug (IND) application in 2026 Updated clinical data of Claudin 18.2 ADC EO-3021 demonstrate ORR of 22.2% in biomarker-enriched patient population; electing to discontinue further... Read More

Dosing ongoing in Phase 1 clinical trial cohorts evaluating Claudin 18.2 ADC EO-3021 in combination with ramucirumab or dostarlimab in patients with advanced gastric/gastroesophageal junction (GEJ) cancer Expect to report initial data from combination cohorts in 4Q 2025 or 1Q 2026 On-track to report additional monotherapy data from dose escalation and expansion cohort of ongoing Phase 1 clinical trial in 2Q 2025 Preclinical... Read More

BOSTON , Feb. 25, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that members of management will participate in upcoming investor conferences in March: TD Cowen 45 th Annual Health Care Conference. Fireside... Read More

Initiated dosing in Phase 1 clinical trial cohort evaluating Claudin 18.2 ADC EO-3021 in combination with ramucirumab or dostarlimab in patients with advanced gastric/gastroesophageal junction (GEJ) cancer Expect to report initial data from combination cohort in 4Q 2025 or 1Q 2026 On-track to report additional monotherapy data from dose escalation and expansion cohorts of ongoing Phase 1 clinical trial in 1H 2025 Plan to... Read More

EO-1022 is comprised of seribantumab, an anti-HER3 monoclonal antibody, and an MMAE payload Following recently signed global license agreement with Synaffix, EO-1022 leverages the company's GlycoConnect® and HydraSpace® ADC technologies for glycan site-specific conjugation and SYNstatin E™ linker-payload Elevation Oncology expects to present EO-1022 preclinical data in 1H 2025 and to file an IND application in 2026 BOSTON ,... Read More

Treatment with both combination regimens demonstrates synergistic anti-tumor activity, supporting planned combination strategy for EO-3021 in patients with gastric or gastroesophageal junction (GEJ) cancer On-track to initiate dosing in combination portion of the ongoing Phase 1 clinical trial of EO-3021 in the fourth quarter of 2024 BOSTON , Dec. 5, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative... Read More

BOSTON , Nov. 26, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph J. Ferra , President and Chief Executive Officer of Elevation Oncology, will participate in a fireside chat at the Piper Sandler 36... Read More

Promising initial Phase 1 data of EO-3021 reported in August highlighting 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile Progressed into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 -- Expect to present preclinical data on the combination potential of EO-3021 with VEGFR2 or PD-1 inhibitors at ESMO... Read More

BOSTON , Sept. 23, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to EO-3021, a differentiated antibody drug conjugate... Read More

BOSTON , Sept. 3, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph J. Ferra , Chief Executive Officer of Elevation Oncology, will participate in a fireside chat at the H.C. Wainwright 26 th Annual... Read More

Today announced promising initial data from Phase 1 clinical trial of EO-3021; 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile Advancing into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 Secured clinical supply agreements to evaluate EO-3021 in combination with ramucirumab and dostarlimab with Lilly and GSK,... Read More

42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer EO-3021 demonstrated differentiated safety profile, with minimal MMAE-associated toxicities, including no neutropenia or peripheral neuropathy/hypoesthesia Advancing into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 Expect to initiate dosing in combination portion of Phase 1 trial by year-end... Read More

Plan to evaluate EO-3021 in combination with ramucirumab and dostarlimab; entered into clinical supply agreements with Lilly and GSK, respectively Expect to initiate dosing in combination portion of the Phase 1 trial by year-end 2024 Combination cohorts broaden market opportunity for EO-3021 to address unmet needs across second- and first-line gastric or gastroesophageal junction cancer settings On-track to provide update... Read More

BOSTON , May 7, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph J. Ferra , Chief Executive Officer of Elevation Oncology, will participate in a fireside chat at the Citizens JMP Life Sciences... Read More

Enrollment ongoing in Phase 1 clinical trial of EO-3021 in the U.S. and Japan ; expect to announce initial safety and efficacy data by mid-3Q 2024, with additional data in 1H 2025 Presented preclinical proof-of-concept data for HER3-ADC program at AACR Annual Meeting; on-track to nominate development candidate in 2H 2024 Raised $44.2 million year-to-date through ATM facility, extending cash runway into 2026 BOSTON , May 2,... Read More

On-track to nominate development candidate in 2024 BOSTON , April 8, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced new preclinical data demonstrating proof-of-concept for its differentiated HER3-ADC program.... Read More

Expanded ongoing Phase 1 clinical trial of EO-3021 globally, dosing first patient in Japan ; on track to provide update in mid-2024 and to report additional data in 1H 2025 Preclinical proof-of-concept data for HER3-ADC program to be presented at AACR Annual Meeting; plan to nominate development candidate in 2024 Raised approximately $17.0M in net proceeds through at-the-market (ATM) facility and refinanced debt facility... Read More

Data support ongoing development of antibody-drug conjugate (ADC) program targeting HER3-expressing cancers On-track to nominate development candidate in 2024 BOSTON , March 5, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical need,... Read More

BOSTON , March 4, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the appointments of Julie Cherrington , Ph.D. and Alan Sandler , M.D., to its Board of Directors. "We are thrilled to welcome Julie and Alan as... Read More

BOSTON , Feb. 28, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that members of management will participate in upcoming investor conferences in March: TD Cowen 44 th Annual Health Care Conference. Fireside... Read More

On track to provide update from ongoing Phase 1 clinical trial in mid-2024; additional data expected in 1H 2025 BOSTON , Feb. 22, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that it has expanded its... Read More

BOSTON , Jan. 22, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the appointment of Darcy Mootz, Ph.D., to its Board of Directors. Dr. Mootz is an experienced life sciences executive, who brings expertise... Read More

Update from Ongoing Phase 1 Clinical Trial of EO-3021 Now Expected Mid-2024 Expanding EO-3021 Clinical Development Program to Include Combination Strategy Announcing HER3-targeting ADC as Second Pipeline Program; Development Candidate Nomination in 2024 Entering 2024 in Strong Financial Position, with Cash into 2H 2025 BOSTON , Jan. 5, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology... Read More

BOSTON , Nov. 22, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph J. Ferra , Chief Executive Officer of Elevation Oncology, will participate in a fireside chat at the Piper Sandler 35 th Annual... Read More

Enrollment is ongoing in the Phase 1 clinical trial evaluating EO-3021 in patients with advanced solid tumors likely to express Claudin 18.2; preliminary safety and anti-tumor activity data expected in 1H 2025 BOSTON , Nov. 2, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of... Read More

NEW YORK , Sept. 5, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph Ferra , Chief Executive Officer of Elevation Oncology, will present at the H.C. Wainwright 25 th Annual Global Investment... Read More

NEW YORK , Aug. 16, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating EO-3021 in patients with advanced unresectable or metastatic... Read More

Initial Phase 1 SYSA1801 (EO-3021) data presented by partner CSPC Pharmaceutical Group Limited at ASCO 2023 showed promising signs of efficacy, including a 47.1% ORR in patients with resistant/refractory gastric cancer expressing Claudin 18.2, with a well-tolerated safety profile Closed underwritten public offering generating net proceeds of $46.5 million , providing cash runway into the second half of 2025 On track to... Read More

NEW YORK , July 13, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, announced today the appointment of Joseph Ferra , M.B.A., as its Chief Executive Officer. Mr. Ferra was previously Interim Chief Executive Officer and Chief... Read More

NEW YORK , June 8, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the pricing of an underwritten public offering of (i) 17,810,000 shares of its common stock and, in lieu of common stock to investors that so... Read More

NEW YORK , June 8, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced a proposed underwritten public offering in which it intends to offer and sell (i) shares of its common stock and, in lieu of common stock to... Read More

Initial data showed promising signs of efficacy, including a 47.1% ORR in patients with resistant/refractory gastric cancer expressing Claudin 18.2, with a well-tolerated safety profile Elevation Oncology on track to initiate Phase 1 clinical trial in the US in the second half of 2023 NEW YORK , June 3, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and... Read More

Partner CSPC Pharmaceutical Group Limited's ongoing Phase 1 SYSA1801 (EO-3021) clinical trial data selected for poster presentation and poster discussion at ASCO 2023 Presented EO-3021 preclinical proof-of-concept data at AACR 2023 which demonstrated anti-tumor activity in models expressing varying levels of Claudin 18.2; clinical case study highlighted SYSA1801 (EO-3021) induced a confirmed partial response in a patient... Read More

NEW YORK , April 26, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that an abstract featuring SYSA1801 (EO-3021) Phase 1 clinical data has been selected for a poster presentation and poster discussion at the... Read More

EO-3021 demonstrated anti-tumor activity in preclinical models expressing varying levels of Claudin 18.2 EO-3021 induced a confirmed partial response in a patient with metastatic gastric cancer Company is on track to initiate a Phase 1 clinical trial in the US in the second half of 2023 NEW YORK , April 17, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery... Read More

Company plans to highlight preclinical proof-of-concept data for EO-3021 in an oral presentation at the New Drugs on the Horizon special session NEW YORK , March 14, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today... Read More

Remain on track to present EO-3021 preclinical proof-of-concept data in first half of 2023, and initiate Phase 1 clinical trial in the US in second half of 2023 Announced pipeline prioritization and realignment of resources focused on advancing EO-3021 Joseph Ferra , Chief Financial Officer, appointed Interim Chief Executive Officer Cash runway extended into the fourth quarter of 2024 NEW YORK , March 9, 2023 /PRNewswire/ --... Read More

NEW YORK , March 1, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that management will participate in the following investor conferences in March: Cowen 43 rd Annual Health Care Conference Date: Tuesday,... Read More

NEW YORK , Feb. 8, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph Ferra , Interim Chief Executive Officer and Chief Financial Officer of Elevation Oncology, will present at SVB Securities Global... Read More

NEW YORK , Jan. 9, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph Ferra , Interim Chief Executive Officer and Chief Financial Officer of Elevation Oncology, will present at the 41 st Annual J.P.... Read More

Prioritizing the development of EO-3021, a potential best-in-class ADC targeting Claudin18.2, and additional pipeline programs including those through its existing partnership with Caris Life Sciences Planning to present EO-3021 preclinical proof-of-concept data at a major medical conference in the first half of 2023, and initiate Phase 1 trial in the US in the second half of 2023; CSPC is actively recruiting patients in an... Read More

NEW YORK , Nov. 30, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced that Shawn M. Leland , PharmD, RPh, Founder and Chief Executive Officer of Elevation Oncology, will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on... Read More